author-photo

Angela Märten

Boehringer Ingelheim

18

Papers

119

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
P51.05 Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P50.03 A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.

2021 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Survie globale des patients atteints de CBNPC EGFRm+ recevant la séquence de traitement afatinib suivi d’osimertinib : analyse actualisée de l’étude GioTag

2020 Revue des Maladies Respiratoires Actualités
Show All
- Source
- Cite
- Save
Citations (0)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.

2020 Future Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases

2020 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (50)
1532PAfatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: Updated data from the GioTag real-world study

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P1.01-118 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
489POverall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)